Research Highlights People with schizophrenia die 15–20 years earlier on average (SMR 2.5–3.5x), develop dementia roughly 20 years earlier, and show metabolic disease in their 20s and 30s. The 2008 “accelerated aging” hypothesis was coined to explain that pattern.1,6,7 A 2026 systematic review of 170 studies argues “advanced aging” fits better than “accelerated aging,” with …
Research Highlights GLP-1 receptor agonists are diabetes drugs (Ozempic, Trulicity, Byetta) being tested in Parkinson’s disease for possible disease-modifying effects. The hypothesis: shared metabolic-inflammatory pathways between type 2 diabetes and Parkinson’s mean drugs that work for one might help the other. A 2026 network meta-analysis pooled 5 trials and 708 patients. Pairwise analysis showed no …
Research Highlights Across 65 studies and 31,495 lupus patients, 4.5% develop psychosis (95% CI 3.6–5.5%). Among patients with neuropsychiatric lupus (NPSLE), the rate jumps to 20.5% (95% CI 10.0–37.6%).1 The 4.5% figure is roughly 50 to 100 times higher than the lifetime prevalence of primary psychotic disorders in age-matched general population samples. Psychosis usually shows …
Media coverage of psychedelics outpaces the trial evidence. MDMA-PTSD signals are large; psilocybin-depression effects shrink against active comparators.
A 1.6M-participant meta-analysis shows a clear gradient: parental schizophrenia hits offspring cognition harder than bipolar, which hits harder than MDD.
CBD has solid evidence for rare pediatric epilepsies, preliminary signal in anxiety and psychosis, and insufficient evidence for most conditions it’s marketed for.
Trauma reminders trigger substance craving — but the path runs through negative emotions, not directly. A 2026 meta-analysis quantifies the link.